Expressions and Significance of Epidermal Growth Factor Receptor, HER-2 and Cyclooxygenase-2 in Gastric Carcinoma_West China Medical Journal

Authors：

LIU Li ¹ ,  JIANG Yong ² , LI Li ² , LIU Duli ¹ , YANG Jiannan ³ , LI Ci ¹ , CHEN Zhiying ¹

1. Department of Pathology, Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610081, P. R. China; 2. Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China; 3. Information Center, Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610081, P. R. China;

Corresponding author：

JIANG Yong, Email: dcaiq@yahoo.com.cn

Keywords：

胃癌; 表皮生长因子受体; 环氧合酶-2; 免疫组织化学

DOI：

CNKI: 51-1356/R.20120115.1546.015

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　探讨胃癌组织中人表皮生长因子受体（EGFR）、表皮生长因子受体-2（HER-2）和环氧合酶-2（COX-2）的表达及与临床病理特征的关系。方法　应用免疫组织化学Envision二步法，检测70例胃癌组织中EGFR、HER-2和COX-2的表达情况，并结合其临床病理特点进行分析。结果　 EGFR、HER-2和COX-2在胃癌组织中的表达阳性率分别为35.7%（25/70）、27.1%（19/70）、67.1%（47/70）。阳性表达与肿瘤分化程度、侵袭深度、有无淋巴结转移及TNM分期有关（P＜0.05），而与患者的性别及年龄、肿瘤部位和大小无关（P gt;0.05）。EGFR、HER-2和COX-2三者之间在胃癌组织中的表达均呈正相关（P＜0.05）。结论　 EGFR、HER-2和COX-2的表达参与胃癌的生长、侵袭和转移过程。它们的联合检测有助于胃癌患者靶向药物的选择，也为胃癌的预后判断提供客观的参考指标。
Objective 　To observe the expressions of epidermal growth factor receptor (EGFR), HER-2 and cyclooxygenase-2 (COX-2) in gastric carcinoma (GC) and to explore the relationship among them. Methods　 The envision immunohistochemical stain method was used to detect EGFR, HER-2 and COX-2 protein expressions in sample of 70 GC tissues. And their corresponding pathologic features were analyzed. Results 　 The positive expression rates of EGFR, HER-2 and COX-2 protein in GC tissue were 35.7% (25/70), 27.1% (19/70) and 67.1% (47/70), respectively. The positive expression rates were closely relevant to the differentiation of the cancer, invasion depth, lymphatic metastasis and TNM (P＜0.05), but not to the patient’ s sex, age, tumor site and size (P＞0. 05). There was a stable positive correlation among EGFR, HER-2 and COX-2 expressions in GC tissues, respectively. Conclusions　 EGFR, HER-2 and COX-2 expressions participate in the development, invasion and metastasis process of GC. Combined detection can be regarded as an important symbol for guiding the molecular targeting therapy of GC, and judging the prognosis of GC.

Citation： LIU Li,JIANG Yong,LI Li,LIU Duli,YANG Jiannan,LI Ci,CHEN Zhiying. Expressions and Significance of Epidermal Growth Factor Receptor, HER-2 and Cyclooxygenase-2 in Gastric Carcinoma. West China Medical Journal, 2012, 27(1): 66-69. doi: CNKI: 51-1356/R.20120115.1546.015 Copy

1.	Bang YJ, van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697.
2.	Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy[J]. Clin Cancer Res, 2008, 14(20): 6371-6375.
3.	Abad A. New drugs in the treatment of gastric tumors[J]. Clin Transl Oncol, 2008, 10(5): 256-261.
4.	Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer[J]. Br J Cancer, 2009, 100(2): 298-304.
5.	吴军, 叶正宝, 马韬, 等. 西妥昔单抗联合FOL FOX4治疗晚期胃癌一例报道[J]. 外科理论与实践, 2008, 13(3): 282-283.
6.	Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004, 351(4): 337-345.
7.	Jorgensen JT. Targeted HER-2 treatment in advanced gastric cancer[J]. Oncology, 2010, 78(1): 26-33.
8.	Okines AF, Cunningham D. Trastuzumab in gastric cancer[J]. Eur J Cancer, 2010, 46(11): 1949-1959.
9.	Saikawa Y, Sugiura T, Toriumi F, et al. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15 [J]. Anticancer Res, 2004, 24(5A): 2723-2728.
10.	Kundu N, Walser TC, Ma X, et al. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease[J]. Cancer Immunol Immunother, 2005, 54(10): 981-987.
11.	Zhao Y, Zhou S, Heng CK. Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells[J]. J Vasc Res, 2009, 46(1): 64-72.
12.	Yu J, Tang BD, Leung WK, et al. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin implications on chemoprevention[J]. World J Gastroenterol, 2005, 11(1): 41-45.
13.	Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors[J]. BMC Cancer, 2008, 8: 237.

1. 　Bang YJ, van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697.
2. 　Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy[J]. Clin Cancer Res, 2008, 14(20): 6371-6375.
3. 　Abad A. New drugs in the treatment of gastric tumors[J]. Clin Transl Oncol, 2008, 10(5): 256-261.
4. 　Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer[J]. Br J Cancer, 2009, 100(2): 298-304.
5. 　吴军, 叶正宝, 马韬, 等. 西妥昔单抗联合FOL FOX4治疗晚期胃癌一例报道[J]. 外科理论与实践, 2008, 13(3): 282-283.
6. 　Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004, 351(4): 337-345.
7. 　Jorgensen JT. Targeted HER-2 treatment in advanced gastric cancer[J]. Oncology, 2010, 78(1): 26-33.
8. 　Okines AF, Cunningham D. Trastuzumab in gastric cancer[J]. Eur J Cancer, 2010, 46(11): 1949-1959.
9. 　Saikawa Y, Sugiura T, Toriumi F, et al. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15 [J]. Anticancer Res, 2004, 24(5A): 2723-2728.
10. 　Kundu N, Walser TC, Ma X, et al. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease[J]. Cancer Immunol Immunother, 2005, 54(10): 981-987.
11. 　Zhao Y, Zhou S, Heng CK. Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells[J]. J Vasc Res, 2009, 46(1): 64-72.
12. 　Yu J, Tang BD, Leung WK, et al. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin implications on chemoprevention[J]. World J Gastroenterol, 2005, 11(1): 41-45.
13. 　Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors[J]. BMC Cancer, 2008, 8: 237.

West China Medical Journal

Expressions and Significance of Epidermal Growth Factor Receptor, HER-2 and Cyclooxygenase-2 in Gastric Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content